ArticleJournal of nanobiotechnology2026
Dissolvable silk microneedles delivering minocycline-loaded ZIF-8 nanoparticles for targeted modulation of sebocyte metabolism and improved acne therapy.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcne Vulgaris (AV) lesions exhibit an acidic, sebum-rich, and inflammation-prone microenvironment in which conventional minocycline therapy is constrained by the stratum-corneum barrier and systemic exposure. Here, we present the fabrication and application of dissolvable silk fibroin microneedles encapsulating minocycline-loaded zeolitic imidazolate frameworks (Mino@ZIF-8/SF MNs) to achieve sebaceous gland-targeted, pH-responsive delivery and multimodal therapy.
resultsThe Mino@ZIF-8/SF MNs display uniform conical morphology, excellent mechanical robustness (peak failure force ≈ 0.4 N per needle), rapid dissolution (< 1 min), high drug loading (≈ 40.11%) and encapsulation efficiency (≈ 70.2%), and negligible hemolytic activity. Under mildly acidic conditions (pH 5.5), minocycline release was markedly accelerated compared to physiological pH 7.4, reflecting the acidified acne microenvironment. Functionally, Mino@ZIF-8/SF MNs achieved > 95% inhibition of Cutibacterium acnes at 30 µg/patch and substantially attenuated sebocyte inflammatory responses. In heat-killed C. acnes-stimulated SZ95 sebocytes, the Mino@ZIF-8/SF MNs downregulated NFKB1, IL-1α, IL-1β, IL-6, IL-8 and MMP9 expression, along with suppression of cytokine-cytokine receptor interaction, IL-17 and NET-associated signaling pathways. RNA-sequencing also suggested that sebocyte metabolism may undergo reprogramming involving enhanced apoptosis, maintenance of mitochondrial oxidative activity, and modulation of PPARγ-related lipid metabolism, which could collectively contribute to reduced lipid droplet accumulation. In a C. acnes-induced acne-like mouse model, Mino@ZIF-8/SF MNs markedly accelerated lesion resolution, reduced lesion elevation, eschar formation, and diameter scores, normalized epidermal thickness, and decreased sebaceous lipid accumulation, while exhibiting no detectable systemic toxicity as confirmed by histology, hematology, and serum biochemistry.
conclusionCollectively, this study establishes a nanobiotechnology platform that integrates metal-organic frameworks(MOF)-based pH-responsive delivery with antibacterial, anti-inflammatory, and metabolic reprogramming activities, offering a precise and minimally invasive multimodal strategy for sebaceous gland-targeted acne therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.